ALGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Align Technology (ALGN) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 available, but it is also not a sell. My direct view is HOLD. The business fundamentals are improving and analyst sentiment is constructive, yet the technical setup is weak and there is no proprietary buy signal today. Since the user is impatient and does not want to wait for an ideal entry, this is still not the best immediate purchase compared with cleaner setups.
ALGN is trading at 168.46, essentially flat after hours, but the regular session was weak at -3.19%. The trend remains soft: MACD histogram is -2.2 and still expanding below zero, which supports bearish momentum. RSI at 31.63 is near oversold but not yet a clear reversal signal. Moving averages are converging, suggesting the stock may be trying to stabilize, but price is still below the pivot at 178.90 and below resistance levels at 188.44 and 194.34. Near-term pattern data also leans negative, with expectations of -1.87% over the next week and -2.85% over the next month.
Recent catalysts are constructive: Q1 2026 revenue rose 6.21% YoY, net income grew 20.96% YoY, EPS increased 23.62% YoY, and gross margin improved to 70.82%. News also included a $200 million share repurchase plan, which is supportive for shareholder value. Analyst sentiment has improved meaningfully, with several firms raising targets and reiterating bullish views, including Piper Sandler, HSBC, Barclays, Evercore ISI, and Citi. The most positive takeaway is that underlying business momentum appears to be recovering.
Short-term price action is poor, with the stock down sharply in the regular session and technical momentum still negative. Options positioning leans bearish, with put demand exceeding call demand. The near-term pattern outlook is also negative. While analysts are more optimistic, the market is not confirming that optimism yet. There are no recent politician, insider, or congress trading signals to provide a positive catalyst.
Latest quarter: Q1 2026. Financial performance was solid and improving. Revenue reached $1.040 billion, up 6.21% YoY. Net income rose 20.96% YoY to $112.8 million, EPS increased 23.62% YoY to $1.57, and gross margin expanded to 70.82%. This shows better profitability and healthier operating leverage, which is favorable for a long-term thesis.
Analyst sentiment is broadly positive and improving. Recent target increases came from Evercore ISI ($220 from $200, Outperform), Morgan Stanley ($188 from $169, Equal Weight), Piper Sandler ($235 from $220, Overweight), Citi ($240, Buy initiation), Barclays ($200 upgrade to Overweight earlier), and HSBC ($200 upgrade to Buy). Wall Street pros are seeing improving orthodontic demand and better volume trends, while the cautious side still points to a weak macro backdrop for dental spending and mixed practice volumes. Net: the pros are leaning bullish, but the stock still needs technical confirmation.
